Callan Family Office LLC Invests $1.37 Million in Astera Labs, Inc. $ALAB

Callan Family Office LLC bought a new stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the second quarter, Holdings Channel.com reports. The fund bought 2,830 shares of the company’s stock, valued at approximately $1,367,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in Astera Labs by 167.3% in the first quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock worth $9,097,000 after buying an additional 95,409 shares during the period. AQR Capital Management LLC grew its holdings in shares of Astera Labs by 213.4% during the 1st quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock worth $680,000 after acquiring an additional 7,756 shares during the period. Empowered Funds LLC grew its holdings in shares of Astera Labs by 917.3% during the 1st quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock worth $277,000 after acquiring an additional 4,183 shares during the period. First Trust Advisors LP raised its position in shares of Astera Labs by 102.0% in the 2nd quarter. First Trust Advisors LP now owns 112,766 shares of the company’s stock worth $10,196,000 after acquiring an additional 56,952 shares in the last quarter. Finally, Brown Advisory Inc. raised its position in shares of Astera Labs by 54.9% in the 2nd quarter. Brown Advisory Inc. now owns 5,581 shares of the company’s stock worth $505,000 after acquiring an additional 1,977 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Buying and Selling at Astera Labs

In other news, CEO Jitendra Mohan sold 90,630 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $340.35, for a total transaction of $30,845,920.50. Following the completion of the transaction, the chief executive officer directly owned 1,266,665 shares in the company, valued at $431,109,432.75. This trade represents a 6.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jack R. Lazar sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $355.17, for a total value of $3,551,700.00. Following the transaction, the director owned 75,688 shares of the company’s stock, valued at $26,882,106.96. The trade was a 11.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 419,244 shares of company stock valued at $163,135,169 in the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ALAB shares. Citigroup restated a “buy” rating on shares of Astera Labs in a research note on Wednesday, July 29th. Stifel Nicolaus upped their price target on Astera Labs from $260.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Morgan Stanley increased their price objective on Astera Labs to $335.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Jefferies Financial Group raised their price objective on Astera Labs from $270.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Astera Labs from $205.00 to $280.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Astera Labs has an average rating of “Moderate Buy” and a consensus target price of $333.00.

Astera Labs Stock Performance

ALAB stock opened at $284.97 on Monday. The firm has a 50 day moving average price of $352.70 and a 200-day moving average price of $245.57. Astera Labs, Inc. has a 52-week low of $97.89 and a 52-week high of $499.48. The firm has a market capitalization of $49.44 billion, a price-to-earnings ratio of 141.07 and a beta of 3.84.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. The firm had revenue of $392.40 million for the quarter, compared to analysts’ expectations of $360.85 million. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%.The business’s revenue for the quarter was up 104.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.44 EPS. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. As a group, sell-side analysts forecast that Astera Labs, Inc. will post 2.7 earnings per share for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.